DRREDDYBSEDr Reddys Laboratories LtdHighPositive
Announced Tue, 12 May · 16:49 IST

Dividend updates

Corporate Actions View source PDF

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.7%1-day move
₹1267.50
prior close
₹1245.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+1.5+1.7+2.1+2.7+6.0+5.0+5.2+4.2+3.4+0.1+0.9-2.4
Up moveDown movePending
AI summary

Dr. Reddy's Board recommended a final dividend of Rs. 8 per equity share (800% of face value Rs. 1) for FY25-26, subject to shareholder approval at the 42nd AGM on July 23, 2026. The record date for determining eligible shareholders is July 10, 2026. The company reported FY26 revenues of Rs. 335.9 billion (up 3.2% YoY) with profit after tax of Rs. 42.9 billion, though Q4FY26 saw significant decline due to lower Lenalidomide sales, one-time Shelf Stock Adjustment of Rs. 4,530 million, and impairments related to discontinued CAR-T programs. North America revenues fell 22% YoY to Rs. 113.7 billion due to lenalidomide impact.

Likely market impact

The dividend of Rs. 8 per share represents a steady income return for shareholders. However, the weak Q4FY26 results with 90% YoY decline in profit before tax may create near-term stock price pressure despite the annual dividend declaration.